Barclays Sticks to Its Hold Rating for Segro plc (REIT) (SGRO)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
May covers the Real Estate sector, focusing on stocks such as Unibail Rodamco Westfield, Hammerson plc R.E.I.T., and Big Yellow Group. According to TipRanks, May has an average return of 1.7% and a 49.86% success rate on recommended stocks.
In addition to Barclays, Segro plc (REIT) also received a Hold from Jefferies's Mike Prew in a report issued on July 10. However, on July 7, J.P. Morgan reiterated a Buy rating on Segro plc (REIT) (LSE: SGRO).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
PARSIPPANY, N.J., August 11, 2025--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.400% senior notes due 2025 in the aggregate principal amount of $600 million, and (iii) the remainder for general corporate purposes. The offering is expected to close on August 18, 2025, subject to customary closing conditions. Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC's website at Alternatively, the issuer, the underwriters or any dealer participating in the offering will arrange to send the prospectus and prospectus supplement upon request by calling Barclays at 1-888-603-5847, BofA Securities at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P. Morgan at 212-834-4533 and MUFG at 1-877-649-6848. These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. DISCLOSURE NOTICES Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at or on request from Zoetis. ZTS-CORZTS-IRZTS-FIN View source version on Contacts Media:Jennifer Albano1-862-399-0810 (o) Laura Panza1-973-975-5176 (o) Investor:Steve Frank1-973-822-7141 (o) Nick Soonthornchai1-973-443-2792 (o) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 hours ago
- Business Insider
‘Too Many Red Flags,' Says Top Investor About Tesla Stock
Tesla (NASDAQ:TSLA) stock has faced a rough ride in 2025, with shares sliding sharply before staging a recovery in recent months – yet still leaving investors down about 15% year-to-date. At the heart of this downturn is a slowdown in EV sales, pressured by intensifying competition – particularly from Chinese rivals – and a tarnished brand image fueled by CEO Elon Musk's constant forays into politics. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The sales trend has been moving in the wrong direction for some time: Q2 2025 marked the second straight year-over-year decline, and even the ever-optimistic Musk conceded that the company could be in for a 'rough' couple of quarters. While that's a sobering admission, Tesla's future isn't devoid of promise. The company is working on multiple ambitious fronts, from full self-driving technology to autonomous robots and AI initiatives. But whether Tesla is actually on the right track to capture those opportunities is a point of contention. One top investor known by the pseudonym Noah's Arc Capital Management is worried that Tesla is not positioning itself to take full advantage of these vast opportunities. 'Tesla's growth momentum has faltered, and this downturn was more than just a blip,' explains the 5-star investor, who is among the top 2% of TipRanks' stock pros. It is not just the slowing EV numbers that have Noah's Arc up in arms, but a lack of discipline that the company seems to be demonstrating. The investor is anxious to see Tesla focus more on full self-driving, believing this to be the big money maker going forward. Instead, Noah's Arc is dismayed that Musk is chasing political sideshows and marginal business ventures (such as the Tesla Diner). 'His attention is divided among so many different endeavors, and Tesla is only getting a small share of that,' adds Noah's Arc. That's never an ideal scenario, but it becomes even more damaging when the company's full self-driving ambitions remain far behind Alphabet's Waymo. And yet, even with the most recent drop in share price, Tesla continues to trade at a 'stretched' valuation, with a Forward Price-to-Earnings multiple north of 190x. This, according to Noah's Arc, leaves nary any 'margin for error.' 'I'm double-downgrading Tesla from strong buy to hold due to Musk's distractions and operational risks outweighing prior bullishness,' sums up Noah's Arc. (To watch Noah's Arc's track record, click here) That's right around where Wall Street finds itself as well. With 14 Buy, 15 Hold, and 8 Sell ratings, TSLA has a consensus Hold (i.e. Neutral) rating. Its 12-month average price target of $307.23 implies ~11% downside from current levels. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
10 hours ago
- Business Insider
SPY ETF News, 8/11/2025
How is SPY stock faring? The SPDR S&P 500 ETF Trust has risen 1.63% over the past five days and is up 9.37% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, SPY is a Moderate Buy. The Street's average price target of $710.54 for the SPY ETF implies an upside potential of 11.51%. Currently, SPY's five holdings with the highest upside potential are Moderna (MRNA), Charter Communications (CHTR), Eli Lilly (LLY), Caesars Entertainment (CZR), and Loews (L). (PLTR), Garmin (GRMN), Dollar Tree (DLTR), Tesla Motors (TSLA), and Altria (MO). Revealingly, SPY's ETF Smart Score is seven, implying that this ETF is likely to perform in line with the market. Power up your ETF investing with TipRanks. Discover the ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.
